Human Leukocyte Antigen–Disease Associations in Rheumatoid Arthritis

Drongelen, Vincent van; Holoshitz, Joseph

doi:10.1016/j.rdc.2017.04.003

Cited by 111 publications

(64 citation statements)

References 103 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In rheumatic diseases, a human leukocyte antigen (HLA)-restricted T cell response to antigen has been shown to affect disease progression, with several HLA alleles associated with disease severity. 3 It was revealed that HLA-DRB1*11 and variant major histocompatibility complex (MHC) class II contributed to the development of JIA, while a “shared epitope” encoded by HLA-DRB1 alleles was correlated with the typical characteristics of both JIA and rheumatoid arthritis (RA). An expressions of HLA-DR4 and HLA-DRw6+ were correlated with articular symptoms in patients with AOSD.…”

Section: Introductionmentioning

confidence: 99%

Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease

Jung

Choi

Sayeed

et al. 2018

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

We examined the expression of human leukocyte antigen (HLA) and composition of differentiated T cells in the peripheral blood to understand the characteristics of the immune changes in patients with adult-onset Still’s disease (AOSD). This study enrolled patients with AOSD (n = 14), patients with rheumatoid arthritis (RA, n = 20), and healthy controls (HC, n = 20). The percentage of surface-stained cells with HLA-DP, DQ, and DR alleles and the composition of differentiated T cells in peripheral blood leukocytes (PBLs) were evaluated by flow cytometry. AOSD patients exhibited significantly higher percentages of lymphocytes presenting HLA-DP and HLA-DR, and lower percentages of cells presenting HLA-DQ, than RA patients or HC. The proportions of CD4+, CD4+CCR7+, CD4+CD62L–, and CD8+CD62L– cells from PBLs were decreased in AOSD patients relative to RA patients or HCs. By contrast, AOSD patients had higher proportions of CD8+naïve T cells in whole blood relative to RA patients or HC. The proportions of CD4+ effector memory T cells, CD8+ naïve T cells, and CD8+ effector memory T cells in whole blood cells and CD4+ effector memory T cell in lymphocytes were significantly associated with the systemic score. While the proportions of CD4+, CD8+, CCR7+, CD4+CCR7+, CD4+CD62L–, and CD8+CD62L– cells were significantly decreased in AOSD patients, and the proportion of CD8+naïve T cells was elevated in AOSD and correlated with the systemic score. Further studies of a large cohort of AOSD patients will be necessary to evaluate these markers in the pathogenesis of AOSD.

show abstract

Section: Introductionmentioning

confidence: 99%

Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease

Jung

Choi

Sayeed

et al. 2018

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Second, studies have suggested that AR and RA may share overlapping genetic predisposition since certain genetic variations in immune‐related genes have been linked to increased susceptibility to both AR and RA. For instance, polymorphisms in HLA‐DRB1, TLR4, and CD14 genes are known to be associated with susceptibility to RA and other autoimmune diseases 31,32 . These genes are also shown to be associated with AR‐based on candidate gene association studies 33‐35 …”

Section: Discussionmentioning

confidence: 99%

The association between allergic rhinitis and risk of rheumatoid arthritis: A systematic review and meta‐analysis

Charoenngam

Ponvilawan

Rittiphairoj

et al. 2020

J Evidence Based Medicine

View full text Add to dashboard Cite

Objective To investigate the association between allergic rhinitis (AR) and the risk of rheumatoid arthritis (RA). Methods Potentially eligible studies were identified from MEDLINE and EMBASE databases from inception to November 2019. Eligible cohort study must report relative risk with 95% confidence intervals (95% CIs) of incident RA between AR patients and comparators. Eligible case‐control studies must include cases with RA and controls without RA, and must explore their history of AR. Odds ratio with 95% CIs of the association between AR and RA must be reported. Point estimates with standard errors from each study were combined using the generic inverse variance method. Results A total of 21,824 articles were identified. After two rounds of the independent review by three investigators, two cohort studies and 10 case–control studies met the eligibility criteria. The pooled analysis showed no association between AR and risk of RA (RR = 0.94; 95% CI, 0.73 to 1.20; I2 = 84%). However, when we conducted a sensitivity analysis including only studies with acceptable quality, defined as Newcastle‐Ottawa score of seven or higher, we found that patients with AR had a significantly higher risk of RA (RR = 1.36; 95% CI, 1.12 to 1.65; I2 = 45%). Conclusions The current systematic review and meta‐analysis could not reveal a significant association between AR and RA. However, when only studies with acceptable quality were included, a significantly higher risk of RA among patients with AR than individuals without AR was observed.

show abstract

“…The physiopathology of RA can be described in three phases: i) the triggering of the autoimmune reaction ii) the inflammation and iii) the osteocartilaginous destruction. A major component of genetic susceptibility to RA can be explained by the inheritance of the HLA-DRB1 allele which starts the autoimmune reaction (van Drongelen & Holoshitz, 2017). Particularly, the expression of the HLADRB1*01 and *04 alleles corresponding to the shared epitope induces the presence of the HLA class II molecule on the surface of antigen-presenting cells recognizing the antigens responsible for the immune reaction of RA ( Figure 1) (Roudier, 2000).…”

Section: Physiopathology Of Rheumatoid Arthritismentioning

confidence: 99%

Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis

Reynaud

Lorscheider

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 0.5 to 1% of the world population. Current treatments include on one hand non-steroidal anti-inflammatory drugs and glucocorticoids (GCs) for treating pain and on the other hand disease-modifying anti-rheumatic drugs such as methotrexate, Janus kinase inhibitors or biologics such as antibodies targeting mainly cytokine expression. More recently, nucleic acids such as siRNA, miRNA or anti-miRNA have shown strong potentialities for the treatment of RA. This review discusses the way nanomedicines can target GCs and nucleic acids to inflammatory sites, increase drug penetration within inflammatory cells, achieve better subcellular distribution and finally protect drugs against degradation. For GCs such a targeting effect would allow the treatment to be more effective at lower doses and to reduce the administration frequency as well as to induce much fewer side-effects. In the case of nucleic acids, particularly siRNA, knocking down proteins involved in RA, could importantly be facilitated using nanomedicines. Finally, the combination of both siRNA and GCs in the same carrier allowed for the same cell to target both the GCs receptor as well as any other signaling pathway involved in RA. Nanomedicines appear to be very promising for the delivery of conventional and novel drugs in RA therapeutics.

show abstract

Human Leukocyte Antigen–Disease Associations in Rheumatoid Arthritis

Cited by 111 publications

References 103 publications

Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease

Characteristic patterns of HLA presentation and T cell differentiation in adult-onset Still’s disease

The association between allergic rhinitis and risk of rheumatoid arthritis: A systematic review and meta‐analysis

Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About